Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07454174 · ClinicalTrials.gov registry record · NA
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
A NA study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Richard Fatica.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07454174: Recruiting NA study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Richard Fatica.
NCT07454174 is a NA study of Autosomal Dominant Polycystic Kidney Disease (ADPKD) that is actively recruiting participants, run by Richard Fatica. The registered enrollment target is 20 participants, below the 788-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07454174, a NA study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), is actively recruiting participants, sponsored by Richard Fatica.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 16 week pilot study of the impact of a nutritionist led ketogenic diet (Ren-Nu) supplemented with the medical food KetoCitra on autosomal dominant polycystic kidney disease.
Primary Outcome
Change from baseline of renal function assessment as measured by creatinine based estimated glomerular filtration rate.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Ren-Nu and KetoCitra
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-25 |
| Est. Completion | 2028-02 |
| Phase | NA |
What NCT07454174 shows while recruiting
NCT07454174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 788-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) appearing as the primary indexed condition, and to 1 intervention - of which Ren-Nu and KetoCitra is the first listed.
NCT07454174 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07454174 about?
NCT07454174 is a clinical study titled "Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease". This is a 16 week pilot study of the impact of a nutritionist led ketogenic diet (Ren-Nu) supplemented with the medical food KetoCitra on autosomal dominant polycystic kidney disease.
What is the current status of trial NCT07454174?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-02-25. Estimated completion is 2028-02.
What conditions does trial NCT07454174 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD).
What interventions are being tested in trial NCT07454174?
The interventions under investigation include: Ren-Nu and KetoCitra (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07454174?
This trial is sponsored by Richard Fatica, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07454174 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
RECRUITING · Phase 2
-
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
ACTIVE NOT RECRUITING
-
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI